VERA THERAPEUTICS INC
1 day chart
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate, atacicept, a self-administered fusion protein that blocks both B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Atacicept is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis, kidney transplant, serious disease, and early death. It is also developing MAU868, a monoclonal antibody that neutralizes infection with BK Virus. The Company is also planning to initiate a Phase III clinical trial of atacicept as a potential treatment for patients with LN, a severe renal manifestation of Systemic Lupus Erythematosus (SLE).
Buy US stocks in Australia with $0 brokerage and trade VERA today!
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.